U.S. markets closed

iCAD, Inc. (ICAD)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.8400-0.3100 (-6.02%)
At close: 04:00PM EST
4.8400 0.00 (0.00%)
After hours: 04:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected


Previous Close5.1500
Bid4.8400 x 1800
Ask4.8700 x 1100
Day's Range4.8000 - 5.2650
52 Week Range4.8000 - 21.4400
Avg. Volume223,756
Market Cap121.529M
Beta (5Y Monthly)1.06
PE Ratio (TTM)N/A
EPS (TTM)-0.3680
Earnings DateFeb 22, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ICAD

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • icad inc.
    HSTM: What does Argus have to say about HSTM?HEALTHSTREAM INC has an Investment Rating of HOLD; a target price of $27.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.
    Fair Value
    Economic Moat
    8 days agoArgus Research
View more
  • Simply Wall St.

    Time To Worry? Analysts Are Downgrading Their iCAD, Inc. (NASDAQ:ICAD) Outlook

    The analysts covering iCAD, Inc. ( NASDAQ:ICAD ) delivered a dose of negativity to shareholders today, by making a...

  • GlobeNewswire

    iCAD Announces the Appointment of New Members to its Board of Directors

    Dana Brown and Timothy Norris Irish offer extensive experience in technology, women’s breast health and unique global perspectivesNASHUA, N.H., Jan. 11, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, announced today it has appointed Dana Brown and Timothy Norris Irish as new independent members of the Board of Directors, effective January 10, 2022. As previously announced, the Company also added

  • GlobeNewswire

    iCAD Announces Estimated Q4 and Fiscal Year 2021 Revenues

    Company expects preliminary estimated Q4 2021 revenues to be between $7.8-$8.0 millionNASHUA, N.H., Jan. 04, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, reported select preliminary, unaudited financial results for the fourth quarter and full year of 2021. Based on preliminary, unaudited financial information, the Company expects total revenue for the fourth quarter of 2021 to be between $7.8 a